{"news_desk": "Business", "print_page": null, "section_name": "Business Day", "subsection_name": "Dealbook", "byline": {"original": "By ROBERT CYRAN", "person": [{"rank": 1, "role": "reported", "firstname": "Robert", "organization": "", "lastname": "CYRAN"}]}, "abstract": "It\u2019s not clear, though, how Mr. Bass\u2019s hedge fund, Hayman Capital, has an advantage over experienced generic firms, Robert Cyran of Reuters Breakingviews writes.", "type_of_material": "Blog", "word_count": "429", "lead_paragraph": null, "pub_date": "2015-02-11T14:36:17Z", "document_type": "blogpost", "slideshow_credits": null, "headline": {"main": "Kyle Bass Wields New Weapon in Challenging Drug Makers ", "kicker": "DealBook"}, "snippet": "It\u2019s not clear, though, how Mr. Bass\u2019s hedge fund, Hayman Capital, has an advantage over experienced generic firms, Robert Cyran of Reuters Breakingviews writes.", "multimedia": [{"height": 126, "url": "images/2015/02/12/business/dbpix-bass/dbpix-bass-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/02/12/business/dbpix-bass/dbpix-bass-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 388, "url": "images/2015/02/12/business/dbpix-bass/dbpix-bass-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "388", "xlarge": "images/2015/02/12/business/dbpix-bass/dbpix-bass-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/02/12/business/dbpix-bass/dbpix-bass-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/02/12/business/dbpix-bass/dbpix-bass-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://dealbook.nytimes.com/2015/02/11/kyle-bass-wields-new-weapon-in-challenging-drug-makers/", "keywords": [{"rank": "1", "value": "Acorda Therapeutics Inc", "name": "organizations"}, {"rank": "2", "value": "Biogen Idec Inc", "name": "organizations"}, {"rank": "3", "value": "Celgene Corporation", "name": "organizations"}, {"rank": "4", "value": "Patent and Trademark Office (US)", "name": "organizations"}, {"rank": "1", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "2", "value": "Hedge Funds", "name": "subject"}, {"rank": "3", "value": "Inventions and Patents", "name": "subject"}], "blog": [], "_id": "54dbaf9138f0d838b6ad6303", "source": "The New York Times"}